Crown Bioscience, an American contract research organization, has entered into a strategic partnership with Turbine, a leading virtual biology company, to integrate in silico modeling with advanced tumor organoid platforms.

The collaboration combines Turbine’s Virtual Assays, capable of simulating biological responses across thousands of samples and hundreds of drugs, with Crown Bioscience’s tumor organoid assays built on HUB Organoid Technology.

This integration establishes a connected, closed-loop workflow that links computational prediction with experimental validation.

By incorporating multimodal and drug response data from hundreds of patient-derived tumor organoid models, the partnership aims to enhance the accuracy of predictive insights. Researchers can use Turbine’s simulations to identify and prioritize targets, therapies, and drug combinations, which are then validated through Crown Bioscience’s lab-based organoid systems.

This approach is designed to reduce experimental burden, lower costs, and shorten development timelines, while improving biological relevance and confidence in clinical translation. By focusing resources on the most promising hypotheses early, the model enables faster and more informed decision-making in oncology R&D.

“Translational success depends on how well early insights reflect real patient biology,” said John Gu, CEO of Crown Bioscience. “By integrating predictive modeling with our organoid models, we are creating a more robust foundation for decision-making, one that improves confidence, reduces risk, and accelerates the path to the clinic.”

“Together with Crown Bioscience, we aim to address a key trade-off in drug discovery between scale and translatability,” said Szabolcs Nagy, CEO of Turbine. “Using our Virtual Lab, researchers can already explore millions of hypotheses in silico. By integrating with Crown’s organoid platform, we enable virtual experimentation that better reflects patient biology, helping close the translatability gap.”